Alpha Teknova, Inc.

NASDAQ:TKNO

Drug Manufacturers - Specialty & Generic

Healthcare
$7.88 +4.55%

+$0.23 today

Market cap
$495.68M
Beta
0.63
P/E (TTM)
-16.2
EPS (TTM)
-$0.32
52W Low $1.91High $6.68

Volume 0.30M

Average 0.13M

TKNO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Alpha Teknova, Inc.NASDAQ: TKNO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $3.5M rose 16.3% year over year, behind the +73.5% change in trailing-twelve-month gross profit. Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at -8.4% a year.

Context

  • Gross profit amounted to 33.2% of revenue in FY2025, up 14.0 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +16.3% toward the trailing-twelve-month pace of +73.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.5M+7.8% QoQ
Last fiscal yearDec 2025
$13.44M+85.9% YoY
LTMMar 2026
$13.93M+73.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.3%——
1 year+85.9%——
3-year CAGR-8.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
13.44M USD
Year-over-year change
+85.9%
4-year CAGR
-6.5%

Gross Profit vs competitors

How TKNO compares with its peers on the latest reported figures

  • TKNO's LTM Mar 2026 gross profit of $13.93M is the lowest of the 8 companies compared; the peer median is $158.27M.
  • Its year-over-year change of +73.5% is the highest of 8, against a peer median of +4.9%.
  • Gross profit amounts to 33.3% of revenue for TKNO, versus a peer median of 51.1%.
TKNO Competitors Peer median
Gross Profit for TKNO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TECHBio-Techne CorporationLTM Sep 2026$807.58M +1.5%+1.3%65.8%
RGENRepligen CorporationLTM Jun 2026$400.8M +34.4%-8.6%51.1%
AZTAAzenta, Inc.LTM Sep 2026$274.96M +0.1%+5.6%44.2%
MLABMesa Laboratories, Inc.LTM Mar 2026$158.27M +4.9%+5.8%63.5%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$72.25M +15.0%-64.0%34.6%
BLFSBioLife Solutions, Inc.LTM Mar 2026$63.74M +7.9%+9.8%63.9%
LABStandard BioTools Inc.LTM Mar 2026$41.66M -37.4%+4.7%48.3%
TKNOAlpha Teknova, Inc.LTM Mar 2026$13.93M +73.5%-8.4%33.3%
Peer median (excluding TKNO) $158.27M+4.9%+4.7%51.1%

Competitors are the stored peer set for TKNO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.89M41.42M36.68M37.75M40.52M
Cost of Revenue19.27M23.94M26.39M30.51M27.08M
Gross Profit17.62M17.48M10.3M7.23M13.44M
Gross Margin47.8%42.2%28.1%19.2%33.2%
Research & Development4.31M7.74M5.57M2.76M2.2M
Selling, General & Admin24.17M37.45M34.78M29.47M27.07M
Operating Expenses29.63M67.14M45.86M33.38M30.42M
Depreciation & Amortization2.88M3.17M5.66M6.58M6.34M
EBITDA(9.17M)(25.69M)(25.54M)(19.57M)(10.15M)
EBITDA Margin-24.8%-62.0%-69.6%-51.8%-25.0%
Operating Income(12.01M)(49.66M)(35.56M)(26.15M)(16.98M)
Operating Margin-32.5%-119.9%-96.9%-69.3%-41.9%
Interest Income0213K000
Interest Expense589K0833K687K710K
Other Income / Expenses(629K)268K(1.52M)(687K)(225K)
Income Before Tax(12.64M)(49.39M)(37.08M)(26.83M)(17.2M)
Pre-Tax Margin-34.3%-119.2%-101.1%-71.1%-42.5%
Income Tax Expense(2.83M)(1.92M)(298K)(88K)58K
Net Income(9.8M)(47.47M)(36.78M)(26.75M)(17.26M)
Net Margin-26.6%-114.6%-100.3%-70.9%-42.6%
EPS (Basic)(0.35)(1.69)(1.16)(0.57)(0.32)
EPS (Diluted)(0.35)(1.69)(1.16)(0.57)(0.32)
Weighted Avg Shares28.01M28.08M31.82M46.75M53.48M
Weighted Avg Shares (Diluted)28.01M28.08M31.82M46.75M53.48M

Alpha Teknova, Inc.

NASDAQ:TKNO

Intrinsic Alpha fair value

Locked

Current Price

$7.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.